BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Translational Genomics Research Institute (TGen) And International Genomics Consortium Announce Launch Of The Molecular Profiling Institute


10/19/2005 5:12:25 PM

PHOENIX, Dec. 8 /PRNewswire/ -- The Translational Genomics Research Institute (TGen) and the International Genomics Consortium (IGC) have formed the Molecular Profiling Institute, Inc. (MPI). MPI is a specialty reference laboratory that utilizes discoveries from the Human Genome Project to analyze cancers from individual patients.

"By identifying the individual molecular profile of a person's cancer, MPI helps oncologists and pathologists to provide better customized therapeutic options for their patients," said Robert J. Penny M.D., Ph.D., Chief Executive Officer and President of MPI.

MPI successfully completed its initial investment round by obtaining seed capitalization of $1.35 million.

MPI's first molecular profile program is called Target Now(TM). Launched in September 2003, the program is now available to cancer patients for whom all standard therapies have failed. These patients can have their cancer sampled, profiled, and assessed to determine if one or more drug targets can be identified in their tumor tissue. Utilizing proteomic and genomic technologies, MPI provides oncologists and pathologists with information they can use to determine therapeutic options for their patients -- options that may not have been considered without information provided by the Target Now(TM) analysis.

MPI derives many of its strengths through developing strategic partnerships. The formation of MPI will assist TGen and the IGC in their mission to translate genomic discoveries into enhanced patient care.

"The launch of MPI is consistent with TGen's mission to do excellent science, find ways to move discoveries into the practice of medicine and to spawn the formation of for-profit companies," said Richard Love, TGen's Chief Operating Officer.

MPI was started in collaboration with Scottsdale Healthcare in laboratories at the Virginia G. Piper Cancer Center in Scottsdale.

The institute has also recently formed a strategic partnership with AmeriPath. AmeriPath is one of the leading anatomic pathology laboratory companies in the United States. It offers a broad range of testing and information services used by physicians in the detection, diagnosis, evaluation and treatment of cancer and other diseases and medical conditions.

Through this partnership, AmeriPath's pathologist network, which serves approximately 3.5 million patients, has access to the molecular profiling provided by MPI. AmeriPath will use MPI for its advanced esoteric reference lab and provide assistance with co-marketing and sales.

MPI has entered into an initial licensing agreement with Netherlands-based Agendia where MPI is the sole source provider in the United States of MammaPrint(R), a microarray assay used to provide important prognostic information for individuals with early invasive breast cancer. The test will be available in January 2005 to breast cancer patients nationwide.

About TGen

The mission of the Translational Genomics Research Institute (TGen) is to make and translate genomic discoveries into advances in human health. Translational genomics research is a relatively new field employing innovative advances arising from the Human Genome Project and applying them to the development of diagnostics, prognostics and therapies for cancer, neurological disorders, diabetes and other complex diseases. TGen is focused on personalized medicine and plans to accomplish its goals through robust and diseased-focused research programs and its state-of-the-art bioinformatics and computational biology facilities.

About IGC

The International Genomics Consortium (IGC) is a non-profit medical research foundation established to expand upon the discoveries of the Human Genome Project and other systematic sequencing efforts by combining world-class genomic research, bioinformatics, and diagnostic technologies in the fight against cancer and other complex genetic diseases. IGC serves numerous common, unmet needs including: the standardization of the collection of properly consented tissues of interest, the molecular characterization of these tissues, and standardization in the representation of these results. IGC facilitates the transition of genomic discoveries to improve patient care and increase the speed in which new diagnostic, prognostic and predictive testing, and new drug and treatment regimens are developed.

About AmeriPath

AmeriPath is one of the leading anatomic pathology laboratory companies in the United States. AmeriPath offers a broad range of testing and information services used by physicians in the detection, diagnosis, evaluation and treatment of cancer and other diseases and medical conditions. The company's extensive diagnostics infrastructure includes over 400 pathologists and doctorate-level scientists providing services in over 20 states utilizing 40 independent pathology laboratories, more than 200 hospitals, and their Centers of Excellence.

For further information, please contact: Media, Galen Perry of The Translational Genomics Research Institute, +1-602-343-8423, or mobile, +1-602-377-4734.

Translational Genomics Research Institute (TGen)

CONTACT: Media, Galen Perry of The Translational Genomics ResearchInstitute, +1-602-343-8423, or mobile, +1-602-377-4734



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES